神龙加速器打不开了-加速器哪个好用
TREAT TB, a multi-year project funded by USAID, seeks to contribute to new knowledge regarding shorter, more tolerable treatment regimens for multidrug-resistant tuberculosis (MDR-TB) through clinical trials of priority research questions, targeted operational research benefitting global, regional, and country TB control efforts, and field evaluations of diagnostic tools.
FIND OUT MORE
神龙加速器打不开了-加速器哪个好用
TREAT TB has been implementing the STREAM clinical trial since 2012. STREAM is the world’s largest recruited, multi-country clinical trial to examine shortened regimens for MDR-TB. It is also the first phase III trial to test the efficacy and safety of bedaquiline, one of the newest TB drugs, within a shortened treatment regimen.
FIND OUT MORE
神龙加速器打不开了-加速器哪个好用
Operational research (OR) plays a key role in generating the evidence needed to guide policies and programs. TREAT TB has conducted in-person OR training courses for health professionals in high-TB burden countries, and produced several free online educational resources.
FIND OUT MORE
神龙加速器打不开了-加速器哪个好用
TREAT TB is strengthening capacity to conduct clinical trials, particularly in countries where the burden of TB is greatest. As part of the STREAM trial, TREAT TB supports specialized training for STREAM study teams. TREAT TB also holds regular webinars covering key aspects of clinical trial implementation.
FIND OUT MORE
神龙加速器打不开了-加速器哪个好用
TREAT TB supports community engagement activities at all STREAM clinical trial sites to ensure that community stakeholders are equipped to collaborate on the trial and future research, and are consulted throughout the research cycle. STREAM community advisory boards provide a crucial link between the community and the research team.
FIND OUT MORE
神龙加速器打不开了-加速器哪个好用
TREAT TB provides technical assistance to national TB programs to improve TB control in high-burden settings. In the Philippines, TREAT TB has provided a comprehensive package of technical assistance to support national scale-up of the standard short treatment regimen for MDR-TB and strengthen capacity to conduct operational research.
FIND OUT MORE